Puma Biotechnology (PBYI) Restructuring Costs (2012)

Puma Biotechnology's (PBYI) quarterly Restructuring Costs came in at $12.0 million in Q4 2012, up 84.62% on a QoQ basis from $6.5 million in Q3 2012.

Analysis

Puma Biotechnology (PBYI) Restructuring Costs (2012) Analysis & Trends

Puma Biotechnology (PBYI) has 1 years of Restructuring Costs data on file, last reported at $12.0 million in Q4 2012.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Puma Biotechnology	486.99 Mn	393.08 Mn	44.03 Mn

Historic Data

Download Data